The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 ...

The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate ...

US military under investigation over claims it weaponized ticks to spread insidious disease

US officials have ordered an investigation into the military over claims it may have developed a bioweapon now linked to ...

The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 ...

The contract, awarded by NIH/NIAID, provides up to US $40 million of non-dilutive funding to Vitalex and its collaborator Appili and for the comprehensive development of VXV-01.

University team in West Virginia identifies compound that could change how deadly infections are treated

West Liberty University biology professor Dr. Joseph Horzempa was invited to present his research at George Mason ...